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Summary 
A Bayesian adaptive design is proposed for a comparative two-armed clinical trial 
using decision theoretical approaches. A loss function is specified to consider the cost 
for each patient, and the costs of making incorrect decisions at the end of a trial. At 
each interim analysis, the decision to terminate or to continue the trial is based on 
the expected loss function while concurrently incorporating efficacy, futility and cost. 
The maximum number of interim analyses is not pre-fixed but decided adaptively by 
the observed data. We derive explicit connections between the loss function and the 
frequentist error rates, so that the desired frequentist properties can be maintained for 
regulatory settings. The operating characteristics of the design are able to be evaluated 
on frequentist grounds. Extensive simulations are carried out to compare the proposed 
design with existing ones. The design is general enough to accommodate both continuous 
and discrete types of data. We illustrate the methods with an animal study evaluating 
a medical treatment for cardiac arrest. 
Some key words: Adaptive designs; Decision theory; Group sequential clinical trials; 
Loss function; Martingale convergence theorem. 
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1 Introduction 
When conducting a large-scale efficacy trial, it is important to sequentially monitor 
the trial for ethical, scientific and economic concerns. Using information from the in-
terim analyses to adaptively make decisions during the trial is a dynamic process. Re-
cently, there have been substantial interest and development of statistical methods in 
the adaptive sample size re-estimation design in the frequentist framework (Proschan 
& Hunsberger, 1995; Fisher, 1998; Shen & Fisher, 1999; Lehmacher & Wassmer, 1999; 
Liu & Chi, 2001; and Müller & Schäfer, 2001, among others). Tsiatis & Mehta (2003), 
on the other hand, compare the efficiency of some adaptive designs with the standard 
group-sequential design. An important feature of an adaptive clinical trial is a continual 
updating of the design using accumulated information from prior experience and interim 
data. Such designs carry the Bayesian spirit and naturally fit the Bayesian paradigm. 
However, there has been limited literature in this area using Bayesian decision theoretical 
approaches. 
A variety of Bayesian approaches have been proposed in group sequential trials for 
different purposes. Bayesian designs are compared with frequentist group sequential 
designs using decision theoretical approaches in Berry & Ho (1988) and Lewis & Berry 
(1994). Studies by Eales & Jennison (1992), Cressie & Biele (1994) and Barber & Jenni-
son (2002), among others, search optimal group sequential designs under various settings 
using Bayesian decision theoretical approaches. The maximum sample size/block size is 
pre-determined for all these methods. By using the non-stationary Markov approach, 
Lai (1973) formulates a hypotheses testing problem that minimizes the expected sample 
sizes. 
In this study, we generalize the Bayesian decision theoretical approach by allowing the 
maximum sample size to be random and sequentially determined by the observed data. 
One practical concern with the use of Bayesian methods in the design and conduct of 
clinical trials has been the control of the false-positive error rate in the regulatory setting. 
We use loss functions that explicitly quantify the costs caused by false-positive and false-
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negative decisions. An asymptotic functional relationship can be derived between the 
design parameters of the loss function and the frequentist error rate. We can thus 
maintain the desired frequentist properties, such as type I and II error rates, for the 
designs by choosing an appropriate loss function. Another advantage of such a design 
is that we are able to simultaneously integrate considerations of efficacy, futility, and 
cost in the decision making, whereas the self-designing trials (Shen & Fisher, 1999 and 
Thach & Fisher, 2002) and similar adaptive designs require a separate futility stopping 
rule. It is, therefore, feasible to identify optimal designs with minimum expected sample 
sizes while achieving the specified power. The method is general enough to be applied 
to both continuous and discrete data. 
We formulate the design and inference strategy in Section 2, and explore two typical 
types of outcomes in detail. The extensive simulations that we carry out are presented 
in Section 3, and the methods are illustrated by an example in Section 4. 
2 Bayesian adaptive design with one-step backward induction 
Consider a clinical trial for comparing a treatment T and a control C, where the treat-
ment response is XT and the control response is XC . The block size at each stage is 
denoted by 2Bi, where Bi is the sample size for each treatment arm, and i = 1, 2, .... 
Let X̄ Ti and X̄
 
Ci be the observed mean of the i-th block for the two arms. Let θ be the 
parameter of interest, 
Z ∞ 
¯ ¯Xi = XTi − XCi ∼ F (·|θ), and xdF (x|θ) = θ, −∞ 
where F (x|θ) is the cumulative density function of x given θ. The prior distribution 
for θ is denoted by π(θ) with a prior mean E(θ|π) = δ. For instance, with a normal 
prior density of φ(θ|δ, σ2/B0), it is equivalent to a normal likelihood arising from a 
previous trial of B0 patients with an observed or hypothetical mean δ for the treatment 
difference (Spiegelhalter et al., 1994). In the frequentist’s hypothesis testing framework, 
the one-sided hypotheses are 
H0: θ ≤ θ0 versus H1: θ > 0. 
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The hypotheses to be tested include two scenarios: with (θ0 > 0) and without (θ0 = 0) 
the range of equivalence (Freedman, 1987). If θ is within the equivalence range, there 
is insufficient information to indicate a preference for any one of the treatments. In 
Sections 2.1 and 2.2, we describe the general results and decision rules for the proposed 
design, while we focus on normally distributed data and binary outcomes to illustrate 
the methods in detail in Sections 2.3 and 2.4, respectively. 
2·1 Loss function and decision rules 
Let A and R represent the actions of accepting and rejecting the null hypothesis, re-
spectively. The loss function for each action is defined by 
⎧
⎪ 0, if θ ≤ θ0;⎨
L(θ, A) = ⎪ 
K1, if θ > θ0;⎩ 
⎧
⎪ K0, if θ ≤ 0;⎨
L(θ, R) = ⎪ 
0, if θ > 0.⎩ 
In particular, K0 and K1 are the losses for making the type I and type II errors, respec-
tively. The conventional Bayesian 0 − Ki loss, with i = 0, 1, (Berger, 1985) is a special 
case when θ0 = 0. 
The stopping rule is devised to minimize the loss. The information at each interim 
stage is updated by Bayes theory. Let Xj = {X1, ..., Xj } define the cumulated data up 
to step j; the corresponding information set at that time can be denoted by σ−algebra, 
Fj = σ(Xj). The total cost/loss of terminating the trial at the j-th step is the cost of 
patients, plus the loss of taking one of the two actions, A or R, whichever is smaller. It 
can be expressed as 
j 
Lstop(Xj) = 2K2 
X 





















= K0pr(θ ≤ 0|Fj). 
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At each interim analysis, we can use cumulated data up to that stage and estimate the 
expected loss of continuing the trial by observing one more block of data. Specifically, 
the expected loss of continuing the trial to the (j + 1)-th stage can be expressed as the 
total cost for sampling up to the (j + 1)-th step plus the expected minimum loss of 
accepting or rejecting the null hypothesis, given the data observed up to the j-th step, 
j+1 ´ 
Lcont(Xj) = 2K2 
X 




E{L(θ, A)|F(j+1)}, E{L(θ, R)|F(j+1)}
i¯̄
¯Fj , (2.2) 
i=1 
The outside expectation in (2.2) is with respect to the predictive distribution of the 
treatment difference. Specifically, the predictive density of X can be expressed as 
Z ∞ 
g(x|Xj) = f(x|θ)π(θ|Xj)dθ, 
−∞ 
where f(x|θ) is the probability density of X . Given the observed data up to the j-th 
stage, a critical region, denoted by Rj, is derived from the loss function, 
( 
pr(θ ≤ 0|Fj) K1 
)
Rj = Xj : ≤ , j = 1, 2, ... (2.3)
pr(θ > θ0|Fj) K0 
The acceptance region at each stage, Aj, is the complement of Rj. To search for the 
optimal adaptive design to minimize the expected loss, we use the following two-step 
strategies starting from the first block of data (with j = 1). 
(1) If Lstop(Xj) ≤ Lcont(Xj), we terminate the trial, and the maximum block size is j. 
Then, if cumulative data Xj is in the rejection region Rj, we conclude that the 
new treatment is more effective than the control. Otherwise, the new treatment is 
no more effective than the control. 
(2) If Lstop(Xj) > Lcont(Xj), we continue to observe the (j + 1)-th block and repeat 
steps (1) and (2). 
We use a one-step backward induction algorithm for this decision problem (DeGroot 
1970); the algorithm is illustrated in detail in Section 2.3. The total number of blocks to 
be observed in the trial, denoted by M , is a stopping time, since {M ≥ j} only depends 
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on Xj. In contrast to the sequential designs with a fixed maximum number of blocks, 
M is not pre-fixed but is a random integer. Thus, it is critical to ensure that the trial 
will be terminated with a finite number of interim analyses with the given loss function. 
The following theorem proves that the design will lead to the termination of trial with 
a finite number of blocks. The proof of Theorem 1 is given in the Appendix. 
Theorem 1. If the unit cost for each sample, K2 > 0, then M is a stopping time 
satisfying P (M < +∞ | θ ) = 1. 
2·2 Connections to the frequentist designs 
Bayesian decision-theoretical designs have been compared with the frequentist group 
sequential designs in terms of their frequentist operating characteristics (Heitjan et al, 
1992; and Lewis & Berry, 1994). Bayesian designs often use loss functions, whereas 
frequentist methods use pre-fixed error rates, to determine the sample sizes (Lindley, 
1997). However, the comparisons are mainly empirical, and few theoretical connections 
have been established between these designs and the frequentist properties. We will 
describe an explicit relationship between the design parameters in the loss functions of 
the proposed design and the frequentist type I error rate. 
The design parameters, Ki (i = 0, 1, 2) in the proposed loss function, along with the 
stopping rules, allow us to control the probabilities of type I and type II errors. With 
the specified loss function applied here, it is clear that a design with a set of parameters 
(aK0, aK1, aK2) is equivalent to the design with parameters (K0, K1, K2) for any positive 
value a. Therefore, the ratios of these parameters, K0 : K1 : K2, determine the operating 
characteristics of a design. We first discuss the case with θ0 = 0. 
In a clinical trial, if the loss function indicates that the trial should be terminated 
at step j, there are two possible actions to take: A or R. Based on the Likelihood 
Principle (Berger, 1985), the probability of making a false-positive conclusion at step j 
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is P (Rj|θ = 0), where 
( 




Rj = Xj : ≤ = Xj : pr(θ ≤ 0|Xj) ≤ . 
pr(θ > 0|Xj) K0 K0 + K1 
If all related density functions satisfy the regularity conditions, the posterior distribution 
of θ given Xj is asymptotically normal with the mean and variance equal to their posterior 
mean, δj, and posterior variance, s
2 
j , respectively (Hartigan, Ch. 11, 1983). Thus, under 
H0, pr(θ ≤ 0|Xj) is asymptotically distributed as Φ(−δj/sj), where Φ is the standard 
normal cumulative distribution function. Under H0, δj/sj converges in distribution to 
Z, where Z follows a standard normal distribution. Therefore, we have 
pr(θ ≤ 0|Xj) → Φ(Z), in distribution. 
Note that Φ(Z) follows a uniform distribution on (0, 1). Thus, recall the rejection region 





pr(Rj|θ = 0) → pr Φ(Z) ≤ = , in distribution. 
K0 + K1 K0 + K1 
For θ0 > 0, Rj shrinks as θ0 increases. Therefore, we have 
K1
lim sup pr(Rj|θ = 0) ≤ . 
j→∞ K0 + K1 
For a given type I error rate, α, we may use the above inequality as a guideline to 
choose the value of K1/(K0 + K1) to control the false-positive conclusion probability, 
if the overall sample size is sufficiently large. From equation (2.3), it is clear that Rj 
depends on K0 and K1 only through their ratio, K0/K1. Specifically, we have 
K0/K1 = (1 − α)/α, (2.4) 
by letting K1/(K0 + K1) = α. 
In decision analyses, values in the loss function are often chosen to reflect as closely 
as possible the actual costs incurred in the trial (Gittins & Pezeshk, 2000 and Stallard 
et al., 1999). Here, we may use this as a guideline to decide the costs for each patient in 
the trial, K2. K0 and K1 are often much larger in magnitude relative to K2, implying 
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a great loss for making an incorrect decision at the end of the trial when comparing 
with the unit cost for one sample. For instance, if K2 = $1000 is the cost to enroll 
and treat one patient in the trial, then K1 can be on the magnitude of $100,000,000 
by considering that hundreds of thousands of future patients would not benefit from 
this effective treatment if the trial concludes inefficacy of the treatment at the end. 
Moreover, the design parameters of the loss function play an important role to evaluate 
and control the loss at each interim analysis. Reflected from the specified loss function, 
the trial should continue if the posterior distribution at the interim analysis does not have 
a clear indication for the value of θ one way or the other. The cost of additional patients, 
by the unit of K2, may be paid in order to gain more information about the treatment 
under investigation. If the posterior distribution indicates a clear trend for the mass of 
θ, the terminal decision to identify a better treatment should be made to minimize the 
loss. This is also the time when the cost of enrolling more patients dominates the total 
cost. As pointed by one reviewer, a high value of K1 implies that future patients might 
benefit from a new effective treatment. However, the new treatment may be superseded 
within a few years, which would reduce the “value” of the treatment. We acknowledge 
such a possibility, but it is often difficult to explicitly build this concern prospectively 
into a trial design (Anscombe, 1963 and Eales & Jennison, 1992). 
2·3 Special Case I: Normal responses 
In this section, we focus on continuous outcomes with a normal distribution to elaborate 
the details in the decision making rules and computations. In addition to the results in 
Section 2.2 for general distributions, we will derive a strict upper boundary to control 
the false-positive probability for outcomes with a normal distribution. Let 
¯Xi = X̄ Ti − XCi ∼ N(θ, σ2/Bi), 
where σ2 is known. It is not conceptually different with an unknown variance. The 
prior distribution for θ is assumed to be N(δ, σ2/B0), where B0 can be interpreted as 
the “sample size” for the prior information on the treatment (Spiegelhalter et al, 1994). 
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Thus, we can denote X0 = δ to keep the notation for prior information coherent with 
that from the interim analysis. After data from block j are observed, the posterior 
distribution of θ is N(δj, s
2), wherej 
Pj σ2 i=0 BiXi 2δj = , sj = Pj Pj 
i=0 Bi i=0 Bi 




Rj = Xj : ≤ . 
1 − Φ{(θ0 − δj)/sj} K0 
Note that 
Φ(−δj/sj) 
1 − Φ{(θ0 − δj)/sj} 
is a decreasing function of δj, and 
Φ(−δj/sj ) Φ(−δj/sj) 
sup = ∞, inf = 0. 
δj 1 − Φ{(θ0 − δj)/sj} δj 1 − Φ{(θ0 − δj)/sj} 




cj = arg x : − = 0 . 
1 − Φ{(θ0 − x)/sj} K0 
For the special case without an equivalence range, i.e. θ0 = 0, we can solve cj explicitly. 
To control the frequentist properties, we like to solve the ratio of K0/K1 for any specified 
type I error rate, α. To simplify the notation, let 
h = Φ−1{K1/(K0 + K1)}. 
It is of interest to solve h corresponding to a given α. Note that h ≤ 0 based on the 
general rule for the selection of K0 and K1. Specifically, the assumption that the type I 





=0 Bi be the cumulated sample sizes at stage j including the “sample size” from 
the prior information. Under the null hypothesis of θ = 0, 
δj 
( 
n0δ nj − n0 
)
− ∼ N − √ , , 
sj σ nj nj 
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then the probability of rejecting the null hypothesis at the j-th interim analysis follows 
as √ 
pr(Rj|θ = 0) = pr(δj/sj > h|θ = 0) = Φ 
(
hσ √ nj + n0δ 
) 
. (2.5)
σ (nj − n0) 
To solve h for all j ≥ 1, we need to find an upper boundary for (2.5). Note that the 
right-hand side of (2.5) is a unimodal function of nj. By taking the first derivative for 
√ 
nj, it is clear that the function reaches its maximum at nj = −hσ/δ, and the function 
√ 
increases when nj ≤ −hσ/δ. Therefore, 
√ √(




sup Φ √ ≤ Φ − . (2.6) 
nj σ (nj − n0) σ 
It is worth noting that the h2σ2 − n0δ2 ≥ 0 as long as n0 ≤ nj, which is always the case. 





h1 = − zα + ,σ2 
√ 
where Φ(zα) = 1 − α. In a similar vein, we can solve the corresponding h when nj > 
−hσ/δ. The total number of blocks is at least one, thus nj ≥ n1 for j ≥ 1. When 
√ 
n1 > −hσ/δ, √ √(
hσ nj + n0δ 
) (
hσ n1 + n0δ
)
sup Φ √ ≤ Φ √ . (2.7) 
nj σ (nj − n0) σ (n1 − n0) 
Let the right-hand side of (2.7) equal α, and solve for h. The solution is 
√ 
z1−ασ (n1 − n0) − n0δ 
h2 = √ . 
σ n1 
Now, for any given significance level α, we can determine the ratio of K0/K1 based on 
this upper bound: 
K0 
⎧






2 + n0}; 
= (2.8)√ √K1 ⎪⎩ {1 − Φ(h2)}/Φ(h2), if n1 > {(σδ )2zα 2 + n0}. 
With K0/K1 defined by (2.8), we have 
sup pr(Rj|θ = 0) ≤ α. 
j 
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Note that using the ratio K0/K1 derived from (2.8) leads to a more conservative design 
compared with that using the ratio of K0/K1 = (1 − α)/α from Section 2.2, since the 
former is an absolute upper boundary. 
The one-step backward induction algorithm is used for the evaluation of loss functions 
at each interim analysis. After observing data up to the j-th interim analysis, the loss 
to terminate the trial at the j-th step follows 




Lstop(Xj) = 2K2 
X 
Bi + min K1 1 − Φ 
³ 




We also need to evaluate the predictive loss to continue the trial to the (j + 1)-th block, 
based on data up to the j-th step. The predictive distribution of Xj+1 given observed 




Xj+1|Xj ∼ N δj, s 2 j + Bj+1 . 
For each possible value of Xj+1, say xj+1, we can compute the posterior mean and 
posterior variance recursively as the following: 
σ2njδj + Bj+1xj+1 2δj+1 = , sj+1 = . nj + Bj+1 nj + Bj+1 
The predicted loss of continuing and observing one more block is then 
j+1X



















xj+1 − δj 
) 
, 
−∞ sj+1 sj+1 (sj + σ2/Bj+1)1/2 
where the integral is to the variable xj+1. If Lstop < Lcont, the trial stops at the j-th 
block. Otherwise, we observe the (j + 1)-th block data and the algorithm repeats. 
2·4 Special case II: Binary responses 
In this section we consider another important special case with binary outcomes. Con-




true rates of success are denoted by pt and pc for the new treatment and control group, 
respectively. Then 
XTi |pt ∼ Binomial(Bi, pt), XCi |pc ∼ Binomial(Bi, pc), 
The difference in efficacy is θ = pt − pc. We assume the following prior distributions for 
pt and pc: 
pt ∼ Be(at, bt), pc ∼ Be(ac, bc). 
The density function for θ is 
⎧Z 1 
dbeta(θ + x, at, bt) ∗ dbeta(x, ac, bc)dx, if −1 < θ < 0;⎪
π(θ|at, bt, ac, bc) = 
⎨ 
−θZ 1−θ 
dbeta(θ + x, at, bt) ∗ dbeta(x, ac, bc)dx, if 0 < θ < 1⎪⎩ 
0 
where dbeta(x, a, b) is the density function of the beta distribution with parameters a and 
b. Because of the conjugate nature of the beta distribution, the posterior distributions 
continue to have beta distributions. The sufficient statistic by the end of the j-th stage 
is denoted by 
j j 
(stj , ftj , scj , fcj ), where stj + ftj = 
X 




stj and ftj are the cumulated number of successes and failures observed on the treatment 
arm up to stage j, and the same notations, scj and fcj , are used for the control arm. 
After observing data from block j and terminating the trial, the expected losses for the 
two decisions, A and R, follow 
Z 1 
E{L(θ, A)|Xj} = K1 π(θ|atj , btj , acj , bcj )dθ, 
θ0 (2.9)Z 0 
E{L(θ, R)|Xj} = K0 π(θ|atj , btj , acj , bcj )dθ. −1 
where 
atj = at + stj , btj = bt + ftj , acj = ac + scj , bcj = bc + fcj . 
Following a transformation to the integrals in (2.9), we have 
Z 1−θ0 
E{L(θ, A)|Xj} = K1 dbeta(x, acj , bcj ){1 − pbeta(θ0 + x, atj , btj )}dx 
0 
Z 1 
E{L(θ, R)|Xj} = K0 dbeta(x, acj , bcj )pbeta(x, atj , btj )dx 
0 
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where pbeta(·, a, b) is the cumulative distribution function of Be(a, b). 
The loss of stopping the trial at the j-th block or observing one more block follows 
(2.1) and (2.2), respectively. The expected loss to observe one more block refers to the 
predictive distribution of stj+1 , scj+1 given (stj , scj ) in block (j + 1), which is given by 










scj+1 − scj 
⎞ 
⎟⎠ 
, btj+1 ) , bcj+1 )β(atj+1 β(acj+1 
β(atj , btj ) β(acj , bcj ) 
, 
where β(·, ·) is a beta function. 
Even though it is possible to derive an absolute upper boundary for binary outcomes 
to control the type I error rate as for normal outcomes, the derivation is much more 
tedious compared to that for the normal distribution. In contrast, we can use the 
asymptotic boundary derived in Section 2.2 to choose the ratio of K0/K1 in order to 
control the false-positive rate. An alternative way is to use the normal approximation 
for the binary outcome to apply the boundary in §2.3. 
3 Numerical Results 
We evaluate the operating characteristics of the proposed designs by extensive Monte 
Carlo simulations, and compare them with the performance of the existing group se-
quential designs, including the frequentist designs of Pocock (1977), O’Brien- Fleming 
(1979), and the adaptive self-designing trial (Shen & Fisher, 1999). For a direct com-
parison with the frequentist designs, the true values of θ are given as fixed, which can 
be considered to have a prior with all mass on θ. The block sizes are pre-fixed, by 
letting semi-block sizes B0 = 1, B1 = max{B, 10}, and Bi = B for i ≥ 2. For each 
scenario, the same block sizes are used among the three adaptive designs; and the same 
equal block size, 2B, are used for the Pocock and O’Brien-Fleming, OBF, designs under 
comparison. All simulations are repeated 10,000 times. The rates of type I and type II 
errors and the average total sample number (ASN) for each design are estimated and 
compared among different designs. 
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It is worth noting that the proposed Bayesian design and self-designing trial do 
not enforce a maximum sample size, while the Pocock and O’Brien-Fleming trials have 
maximum sample sizes. We consider one-sided hypothesis testing. The modified one-
sided Pocock and O’Brien-Fleming designs are used to ensure comparability among the 
designs. The maximum number of groups, N , in the designs of Pocock and O’Brien-
√ 
Fleming is obtained from Table 2 in Pocock (1977) with Δ = Bδ/σ, where the block 
size, 2B, is a constant for each stage. For a given N , Pocock’s interim test boundaries 
are of the form 
j√ Á−z < (jB) X Xj (jσ) < z, 
i=1 
where the z value is obtained from Table 1 in Pocock (1977). The asymptotic boundaries 
for O’Brien-Fleming’s one-sided test have the form 
j√ √ √ √Á−zl/{Δ (j)} + 0.5Δ (j) < (jB) 
X 
Xj (jσ) < zu (N/j), 
i=1 
where zl = log{β/(1 − α)} and zu are obtained from DeMets and Ware (1982). 
We first generate normal outcomes with mean θ = 0.5 and variance σ = 1. The value 
of δ is set at 0.4, 0.5, 0.6, and 0.7. Using the guidelines in Sections 2.2 and 2.3, K0/K1 
is determined by (2.8) for “Bayes Adapt I” or by (2.4) for “Bayes Adapt II” in Table 
1 for the given type I error rate of 0.025. The value of K2/K1 is searched to yield the 
frequentist type II error rate empirically for given δ and B. 
Table 1 shows that the frequentist type I error rates are strictly maintained under 
the specified level for the proposed Bayesian designs with either boundary. Because of 
the upper boundary being used to control the type I error rate, the proposed design is 
conservative in terms of the type I error. The magnitude is similar to that of the self-
designing trial, but there is no additional futility stopping rule required for the proposed 
Bayesian designs. It is not surprising that the boundary taking (2.8) is more conservative 
than the other from (2.4), since the former is a strict upper boundary. When the prior 
mean, δ, is over-stated relative to the true treatment efficacy, θ, the frequentist group 
sequential designs with the fixed maximum sample sizes lead to a substantial loss of 
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power. On the other hand, the proposed Bayesian designs and the self-designing trial 
can update the prior information using the observed data through interim analyses. 
It is interesting to note the advantages of the proposed Bayesian designs over the 
self-designing trial in terms of both power and average sample number, ASN, when the 
type I error rates for both designs are maintained. For instance, when the expected 
treatment effect is 40% over-estimated to the true effect, the Bayesian design can still 
maintain almost 90% power, whereas the self-designing trial achieves 77% power. One 
possible reason is that the design based on the decision theoretical approach uses suffi-
cient statistics from interim data, while the self-designing trial does not. Of course, it 
is not surprising that the frequentist group sequential designs have power that is only 
between 60-67% with fixed maximum sample sizes. Figure 1 shows a histogram for 
the number of blocks based on 100 simulated trials. More than 75% of the trials are 
terminated with the number of interim analyses being four or less. 
For binary outcomes, first we are interested in comparisons with the usual fixed 
sample design. We use constant Be(1, 1) and Be(2, 2) priors with block sizes 32 or 48. 
The empirical type I error rates, denoted by α̂, are determined when taking pt = pc = 0.5. 
The frequentist type II error rates are estimated with pt = 0.5 + δ/2 and pc = 0.5 − δ/2. 
Using normal approximation to the binary outcomes, the ratio of K0/K1 in the loss 
function is determined by (2.4). 
Tables 2 shows the frequentist error rates for the proposed Bayesian designs. As 
expected, the proposed Bayesian designs have false-positive probabilities around the 
specified level under the null hypothesis. When the true difference, θ, is smaller than 
the prior mean, δ, the proposed designs can extend the trial and achieve adequate power 
using interim data. In contrast, the usual fixed sample designs do not have the flexibility 
to adjust for the total sample size to achieve the desired power. 
Secondly, we are particularly interested in comparisons with the designs of Lewis & 
Berry (1994), which were proposed for binary outcomes only. To directly compare the 
proposed design with that of Lewis & Berry (1994), we use the same set-up as in their 
simulations, including the same block sizes and priors as in Table 4 of Lewis and Berry 
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and assuming δ = θ. When δ = θ, the proposed design has power similar to that of 
Lewis & Berry’s design, but the average sample number is slightly increased (less than 
5%) under the alternative. Under the null hypothesis, the average sample number is 
smaller for the proposed design than for the design of Lewis and Berry. However, the 
computation of the proposed design is much less intensive compared to that of Lewis 
and Berry’s design, and the implementation is straightforward with one-step backward 
induction. A major difference between the two designs is that the design of Lewis and 
Berry has a pre-fixed maximum number of blocks, while our proposed design does not 
have such a restriction. Thus, the power for the Lewis and Berry design will be reduced 
if θ < δ. 
4 Example 
To illustrate the proposed design, we apply the design to a completed randomized animal 
experiment that evaluated epinephrine in cardiac arrest (Niemann et al., 1992; and 
Lewis & Berry, 1994). The experiment compared cardiac resuscitation outcomes in 
a canine model using the standard therapy, immediately delivering an electric shock, 
versus an alternative therapy, high-dose epinephrine therapy plus conventional CPR, 
before a countershock of prolonged ventricular fibrillation. The study was originally 
designed as a frequentist fully sequential trial to detect an increase in the proportion of 
animals successfully resuscitated from 20% to 60% with the new therapy. The trial was 
terminated after observing outcomes from 28 animals. The observed data are presented 
in the following table, where Sc and St are the cumulative number of successes for each 
block in the control arm and treatment arm, respectively. 
Block 2Bi Sc St 
1 20 3 6 
2 8 3 9 
Using the proposed Bayesian design with 20 animals in the first block and 8 animals 
in the following blocks, K0/K1 = 19, K2 = 0.005, and flat priors of Be(1, 1) for pc 
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and pt, the frequentist type I and type II error rates are 0.035 and 0.834, from Monte 
Carlo simulations. Based on the decision rules from our design, the experiment should 
be terminated at the end of the second block with a total sample size of 28. The null 
hypothesis is then rejected, and the posterior probability that θ > 0 is 0.987. 
5 Discussion 
One new feature of the proposed Bayesian adaptive designs is that the total sample 
size is adaptively determined by prior information and cumulated data, rather than pre-
fixed as in the designs described by Berry & Ho (1988) and Lewis & Berry (1994). The 
design based on a decision theoretical approach, on the other hand, is fundamentally 
different from the adaptive designs developed in the frequentist framework. With the 
flexible loss functions, the proposed designs can be terminated at any stage through 
the loss functions for either futility or superiority of the treatment arm. Thus, we are 
able to simultaneously integrate efficacy, futility, and cost in decision making, whereas 
the self-designing trial and other existing adaptive designs often require dealing with 
these factors separately. Such a unified loss function makes it possible to find optimal 
strategies under a variety of circumstances. 
As elaborated in Lewis & Berry (1994), the use of traditional Bayesian sequential 
designs in the regulatory setting is often hampered by concerns of violating frequentist 
properties. To be consistent with regulatory standards, we propose Bayesian designs that 
are derived and checked to have acceptable frequentist properties. An asymptotic upper 
boundary to control the false-positive error rate through the loss function is derived for 
general distributions, and an absolute boundary is obtained for normal distributions. 
Note that the derivation of (2.4) is based on the Likelihood Principle (Berger, 1985), 
therefore the stopping rules are not taken into account in the calculation of the prob-
ability to reject the null hypothesis at a given stopping time. In contrast, from the 
frequentist view point, the terminal decision probability depends on what stopping rules 
are used, and not just on the observed data (Schervish, 1995). 
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The proposed designs are general enough to accommodate various types of outcomes, 
because the use of one-step backward induction makes it possible to estimate the pre-
dicted losses of different decisions in the monitoring process. In contrast, the M -step 
backward induction used in Lewis & Berry (1994) can be difficult and extremely time 
consuming computationally for continuous outcomes with even moderate M , and is only 
feasible for binary outcomes. Regardless of the computation intensity for M -step back-
ward induction, it is interesting to know how much efficiency may be gained by using 
M -step backward induction compared to one-step backward induction. Intuitively, for 
fully sequential designs, there can be a significant gain when using M -step backward 
induction over one-step backward induction, because only one patient is observed each 
time. On the other hand, for group sequential designs that are commonly used in clin-
ical trials, the data from each block provide adequate information for the prediction. 
As a result, the gain by performing M -step backward induction is minor compared to 
the use of one-step backward induction in group sequential designs, as we found in the 
simulations. However, compared to M -step backward induction, the computation for 
one-step backward induction is much simpler and the algorithm is easier to implement 
for various distributions. In many clinical trials, the primary outcomes of interest often 
need long-term follow-up with potential censoring (Shen and Cai, 2003). To implement 
this design to censored survival data requires further technical modifications. 
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Appendix 
Proof of Theorem 1 
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For j = 1, 2, ..., define 
Yj = min 
h
E{L(θ, A)|Fj}, E{L(θ, R)|Fj}
i 
. 
By Jesen’s inequality, we have 




E{L(θ, A)|F j+1} 
¯̄




E{L(θ, R)|F j+1} 
¯̄
¯ F j 
i´ 
= Yj. 
The stochastic process {(Yj, F j); j ≥ 1} is a nonnegative uniformly bounded super-
martingale process. According to the martingale convergence theorem, Yj converges 
almost surely to a bounded random variable Y∞ (Chung, 1974). Therefore, 
0 ≤ Yj − E(Yj+1|F j) → Y∞ − Y∞ = 0 a.s. as j →∞. 
Let Dj = {Xj : Lstop(Xj) ≤ Lcont(Xj)}, where Lstop(Xj) and Lcont(Xj) are given in 
(2.1) and (2.2), respectively. The above arguments together with the unit cost, K2 > 0, 
imply that pr(Dj) converges to 1. It is equivalent to pr(M < ∞) = 1. 
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Table 1. The comparison of power and average sample number (ASN) between the 
Bayesian designs and other group sequential designs with one-sided α = 0.025, and true 
θ = 0 at null and θ = 0.5 under the alternative 
Design B = 6 B = 8 
δ α̂ ASNα 1-β̂ ASNβ α̂ ASNα 1-β̂ ASNβ 
Pocock 0.4 0.026 174.7 0.985 74.9 0.025 171.3 0.982 78.9 
OBF 0.4 0.022 68.6 0.985 84.4 0.025 70.9 0.984 83.7 
Self-designing 0.4 0.012 84.4 0.911 87.0 0.010 92.9 0.931 90.0 
Bayes Adapt I 0.4 0.014 49.7 0.934 72.7 0.012 59.3 0.959 79.5 
Bayes Adapt II 0.4 0.016 51.1 0.938 72.0 0.017 60.4 0.961 78.3 
Pocock 0.5 0.023 117.2 0.904 68.6 0.024 124.9 0.923 74.0 
OBF 0.5 0.024 47.7 0.929 65.5 0.024 49.7 0.937 69.1 
Self-designing 0.5 0.013 62.5 0.888 78.5 0.014 71.4 0.918 83.9 
Bayes Adapt I 0.5 0.012 45.8 0.921 69.4 0.016 54.4 0.946 75.5 
Bayes Adapt II 0.5 0.018 47.8 0.930 68.2 0.017 54.9 0.951 73.7 
Pocock 0.6 0.025 82.0 0.760 59.7 0.026 94.0 0.811 67.5 
OBF 0.6 0.025 35.0 0.810 50.8 0.214 37.3 0.848 55.9 
Self-designing 0.6 0.013 51.9 0.836 70.3 0.014 59.9 0.869 74.6 
Bayes Adapt I 0.6 0.013 42.0 0.905 66.6 0.013 49.2 0.928 71.7 
Bayes Adapt II 0.6 0.020 45.3 0.914 64.6 0.020 51.3 0.942 69.7 
Pocock 0.7 0.025 58.9 0.595 49.3 0.022 63.1 0.616 54.2 
OBF 0.7 0.024 26.7 0.670 38.1 0.023 28.9 0.668 39.9 
Self-designing 0.7 0.014 43.9 0.761 61.3 0.014 49.3 0.772 65.1 
Bayes Adapt I 0.7 0.015 39.8 0.889 63.9 0.015 45.9 0.920 68.9 
Bayes Adapt II 0.7 0.022 42.7 0.907 61.6 0.021 48.9 0.932 66.1 
Bayes Adapt I: K0/K1 is determined by formula (2.8). Bayes Adapt II: K0/K1 satisfies the equation 
K1/(K1 + K0) = α. For both designs, K2/K1 = 0.14B ∗ δ3 . ASNα and ASNβ are average sample sizes 
under θ = 0 and θ = 0.5, respectively. 
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Table 2. The comparison of power and average sample number (ASN) between the 
proposed Bayesian optimal design and fixed sample design for binary responses; priors 
are Be(1, 1); δ = 0.4; pt = pc = 0.5 for H0; pt = 0.5 + θ/2 and pc = 0.5 − θ/2 for H1 
Proposed Bayesian design II Fixed sample design 
B=16 B=24 
θ P (reject H0) ASN P (reject H0) ASN P (reject H0) ASN 
0.40 0.921 46.0 0.973 55.0 0.906 46 
0.36 0.874 50.4 0.945 57.3 0.835 46 
0.32 0.801 52.3 0.875 60.9 0.741 46 
0.28 0.710 54.0 0.812 64.4 0.631 46 
0.00 0.047 40.2 0.047 56.2 0.050 46 
K0/K1 = 19 which satisfies the equation K1/(K1 + K0) = α for α = 0.05. K2/K1 = 0.005. 
Table 3. The comparison of power and average sample number (ASN) between the 
proposed Bayesian optimal design and Lewis and Berry Bayesian design for binary 
responses; pt = pc = 0.5 for H0; pt = 0.5 + δ/2 and pc = 0.5 − δ/2 for H1 
Proposed Bayesian design II Lewis-Berry’s design 
Priors δ B α̂ ASNα 1 − β̂  ASNβ α̂ ASNα 1 − β̂  ASNβ 
B(1, 1) 0.4 16 0.047 40.2 0.921 46.0 0.039 42.1 0.946 44.3 
0.2 16 0.030 131.4 0.926 171.7 0.035 155.9 0.960 161.4 
B(2, 2) 0.4 16 0.030 40.6 0.942 48.6 0.027 38.3 0.907 46.2 
0.2 16 0.026 125.5 0.917 171.9 0.034 152.3 0.958 162.1 
K0/K1 = 19 which satisfies the equation K1/(K1 + K0) = α for α = 0.05. K2/K1 = 0.005 
for δ = 0.4. K2/K1 = 0.00003 for δ = 0.2. 
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Figure 1: The histogram of the number of blocks in relative frequency, where θ = 0.6, 
δ = 0.6, and B = 12. 
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